189 related articles for article (PubMed ID: 21931626)
1. Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.
Stoll M; Kollan C; Bergmann F; Bogner J; Faetkenheuer G; Fritzsche C; Hoeper K; Horst HA; van Lunzen J; Plettenberg A; Reuter S; Rockstroh J; Stellbrink HJ; Hamouda O; Bartmeyer B;
PLoS One; 2011; 6(9):e23946. PubMed ID: 21931626
[TBL] [Abstract][Full Text] [Related]
2. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Walensky RP; Sax PE; Nakamura YM; Weinstein MC; Pei PP; Freedberg KA; Paltiel AD; Schackman BR
Ann Intern Med; 2013 Jan; 158(2):84-92. PubMed ID: 23318310
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.
Aragão F; Vera J; Vaz Pinto I
PLoS One; 2012; 7(9):e44774. PubMed ID: 23028618
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start.
Angeletti C; Pezzotti P; Antinori A; Mammone A; Navarra A; Orchi N; Lorenzini P; Mecozzi A; Ammassari A; Murachelli S; Ippolito G; Girardi E
HIV Med; 2014 Mar; 15(3):165-74. PubMed ID: 24495188
[TBL] [Abstract][Full Text] [Related]
5. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
[TBL] [Abstract][Full Text] [Related]
6. [Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].
Brunner J; Seybold U; Gunsenheimer-Bartmeyer B; Hamouda O; Bogner JR;
Dtsch Med Wochenschr; 2010 Jun; 135(23):1166-70. PubMed ID: 20514595
[TBL] [Abstract][Full Text] [Related]
7. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
8. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
[TBL] [Abstract][Full Text] [Related]
9. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
[TBL] [Abstract][Full Text] [Related]
10. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
11. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).
Floridia M; Massella M; Bucciardini R; Perucci CA; Rossi L; Tomino C; Fragola V; Ricciardulli D; Galluzzo CM; Giannini G; Pirillo MF; Andreotti M; Mirra M; Vella S
HIV Clin Trials; 2000; 1(2):9-16. PubMed ID: 11590493
[TBL] [Abstract][Full Text] [Related]
12. Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV.
Johnston SS; Juday T; Seekins D; Espindle D; Chu BC
J Manag Care Pharm; 2012 Mar; 18(2):129-45. PubMed ID: 22380472
[TBL] [Abstract][Full Text] [Related]
13. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Ruof J; Dusek A; DeSpirito M; Demasi RA
Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
[TBL] [Abstract][Full Text] [Related]
14. [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients].
Llibre-Codina JM; Casado-Gómez MA; Sánchez-de la Rosa R; Pérez-Elías MJ; Santos-González J; Miralles-Alvarez C; Martínez-Chamorro E; Domingo-Pedrol P; Alvarez-García ML; Moreno-Guillén S
Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):98-107. PubMed ID: 17288907
[TBL] [Abstract][Full Text] [Related]
15. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
16. Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings.
Krentz HB; Campbell S; Gill VC; Gill MJ
HIV Med; 2018 Apr; 19(4):290-298. PubMed ID: 29368401
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
Scherrer AU; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Calmy A; Cavassini M; Elzi L; Vernazza PL; Bernasconi E; Ledergerber B; Günthard HF;
PLoS One; 2012; 7(11):e50307. PubMed ID: 23189194
[TBL] [Abstract][Full Text] [Related]
18. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
[TBL] [Abstract][Full Text] [Related]
19. De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics.
Giraud JS; Doisne M; Chan Hew Wai A; Majerholc C; Fourn E; Sejean K; Trichereau J; Bonan B; Zucman D
PLoS One; 2020; 15(9):e0239704. PubMed ID: 32976493
[TBL] [Abstract][Full Text] [Related]
20. Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019.
Lottes M; Bremer V; Prugger C; Kollan C; Schmidt D
BMC Health Serv Res; 2022 Jan; 22(1):63. PubMed ID: 35027062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
